Buffalo Biolabs, LLC (BBL) and Incuron LLC announced today that Incuron has retained the services of Buffalo Biolabs for preclinical murine studies. The studies, to be conducted in 2014, will advance and enhance the understanding of the efficacy and mechanism of work of Incuron’s flagship compound CBLO137. According to Vladimir Tezov, CEO of Bioprocess Capital, one of Incuron’s investors, Incuron previously “outsourced to BBL several research tasks involving new assay and model development and the outcome exceeds our most optimistic expectations. I expect us broadening our relationships with this company.”
Buffalo Biolabs, LLC (BBL), founded in 2009 by Dr. Andrei V. Gudkov, PhD, DSci, is a Contract Research Organization (CRO) focused on preclinical services and drug discovery, primarily in the fields of oncology, immunology and wound care. BBL operates from its headquarters in Buffalo Niagara Medical Campus.